PillLiraglutide
Brands: Saxenda · Liraglutide
6 active makers
soon
soon
soon
soon
US acquisition costNADAC · per unit
Average across 6 priced NDCs. A benchmark of pharmacy acquisition cost — not a retail quote.
Medicaid dispensing volumeSDUD · per quarter
Prescriptions dispensed under Medicaid (fee-for-service + managed care), summed nationally. The closest free proxy to sales volume — Medicaid only, not all-payer.
Who makes it6 active · 1 exited
US labelers as registered with FDA. Repackagers relabel another company's product; share* is of listed packages, not sales.
| Labeler | Type | Packages | Status |
|---|---|---|---|
| Orbicular Pharmaceutical Technologies Private Limited | unknown | 4 | SUPPLYING |
| Cipla USA Inc. | unknown | 4 | SUPPLYING |
| Hybio Pharmaceutical Co., Ltd. (Pingshan Factory) | unknown | 3 | SUPPLYING |
| Novo Nordisk | unknown | 3 | SUPPLYING |
| Biocon Pharma Inc | unknown | 2 | SUPPLYING |
| A-S Medication Solutions | unknown | 1 | SUPPLYING |
| Teva Pharmaceuticals USA, Inc. | unknown | 1 | EXITED 2027 |
Regulatory & supply eventsFDA · US
Shortages, recalls, and registration changes attached to this drug concept.
- May 14, 2026RESOLVEDShortage resolved: Liraglutide Injection (Teva Pharmaceuticals USA, Inc.)
Liraglutide Injection — reported in shortage by Teva Pharmaceuticals USA, Inc.. Therapeutic category: Endocrinology/Metabolism.
- May 14, 2026SHORTAGEDrug shortage: Liraglutide Injection (Teva Pharmaceuticals USA, Inc.)
Liraglutide Injection — reported in shortage by Teva Pharmaceuticals USA, Inc.. Therapeutic category: Endocrinology/Metabolism.
- Mar 22, 2021RECALLRecall (Class II): Saxenda (liraglutide) Injection, 18 mg/3 mL (6 mg/mL), 1 x 3 mL Prefilled Pen, Sample. Not for Resale., Rx only, Novo N…
Temperature Abuse: product samples were stored at temperatures below 32* F which is not in accordance with storage requirements that could cause a lack of efficacy and damage to the cartridge and pen-injectors. — Recalling firm: Novo Nordisk Inc — Nationwide in the USA